[1] Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology, 2015, 85:177-189. [2] Neuroimmunology Branch, Chinese Society of Immunology.Chinese guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders (2021 edition)[J].Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28:423-436.[中国免疫学会神经免疫分会.中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J].中国神经免疫学和神经病学杂志, 2021, 28:423-436.] [3] Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P.Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment:a prospective web-based multi-center study in multiple sclerosis patients with a relapse[J].J Neurol, 2016, 263:1641-1651. [4] Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida K, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira J.Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica[J].Mult Scler, 2016, 22:1337-1348. [5] Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, Apostolos-Pereira SL, Martynenko Y, Breu M, de Medeiros Rimkus C, Wassmer E, Baumann M, Papetti L, Capobianco M, Kornek B, Rostásy K, da Paz JA, Ciccarelli O, Lim M, Saiz A, Neuteboom R, Marignier R, Hemingway C, Sato DK, Deiva K.Treatment and outcome of aquaporin-4 antibody-positive NMOSD:a multinational pediatric study[J].Neurol Neuroimmunol Neuroinflamm, 2020, 7:e837. [6] Pharmaceutical Hepatology Group, Hepatology Branch, Chinese Medical Association.Diagnosis and treatment guideline on drug-induced liver injury[J].Zhonghua Gan Zang Bing Za Zhi, 2015, 23:810-820.[中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23:810-820.] [7] Danan G, Benichou C.Causality assessment of adverse reactions to drugs:Ⅰ.A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46:1323-1330. [8] Li L, Jiang W, Wang J.Clinical analysis of 275 cases of acute drug-induced liver disease[J].Front Med China, 2007, 1:58-61. [9] Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, Medina-Cáliz I, Sanabria-Cabrera J, Sanjuan-Jiménez R, González-Jiménez A, García-Cortés M, Lucena MI, Andrade RJ, Robles-Díaz M.Liver injury after methylprednisolone pulses:a disputable cause of hepatotoxicity.A case series and literature review[J].United European Gastroenterol J, 2019, 7:825-837. [10] Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, Vukusic S, Vial T.Methylprednisolone liver toxicity:a new case and a French regional pharmacovigilance survey[J].Clin Res Hepatol Gastroenterol, 2017, 41:497-501. [11] Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, Marrone G, Grieco A, Mirabella M.Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients[J].Brain Behav, 2018, 8:e00968. [12] Eguchi H, Tani J, Hirao S, Tsuruta M, Tokubuchi I, Yamada K, Kasaoka M, Teshima Y, Kakuma T, Hiromatsu Y.Liver dysfunction associated with intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy[J].Int J Endocrinol, 2015:ID835979. [13] Kimura H, Takeda A, Kikukawa T, Hasegawa I, Mino T, Uchida-Kobayashi S, Ohsawa M, Itoh Y.Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis[J].Mult Scler Relat Disord, 2020, 42:102065. [14] Padda MS, Sanchez M, Akhtar AJ, Boyer JL.Drug-induced cholestasis[J].Hepatology, 2011, 53:1377-1387. [15] Sha J, Aishanjiang Y, Mayinuer M, Li HY.Recurrent myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis-encephalomyelitis:one case report[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2020, 20:877-880.[沙晶, 艾山江·玉素甫江, 玛依努尔·买买提, 李红燕.复发性抗MOG抗体相关性视神经炎-脑脊髓炎一例[J].中国现代神经疾病杂志, 2020, 20:877-880.] [16] Du M, Jiang ZZ, Zhang LY.Research progress on liver injury caused by commonly used immunosuppressants[J].Yao Wu Ping Jia Yan Jiu, 2022, 45:982-988.[杜敏, 江振洲, 张陆勇.常用免疫抑制剂致肝损伤的研究进展[J].药物评价研究, 2022, 45:982-988.] [17] Mehendale HM.Tissue repair:an important determinant of final outcome of toxicant-induced injury[J].Toxicol Pathol, 2005, 33:41-51. [18] Hassan A, Fontana RJ.The diagnosis and management of idiosyncratic drug-induced liver injury[J].Liver Int, 2019, 39:31-41. |